HIV prevention injection finishes early safety trial
A NEW injection that could prevent HIV infection has successfully completed an early safety trial, according to a report in The Lancet medical journal.
The injection, known as Lenacapavir, works by preventing the virus from multiplying within body cells and could provide protection for an entire year.
Researchers noted that the injection differs from existing preventive measures such as oral and injectable PrEP (Pre-Exposure Prophylaxis) which typically offer protection for only one month.
If future trials are successful, Lenacapavir could become a long-term preventive solution against HIV.
Currently, available treatments focus on suppressing the virus in people already infected and providing short-term prevention through PrEP for individuals at risk such as survivors of sexual assault.
Top Headlines
Trending Stories
© 2025 IPPMEDIA.COM. ALL RIGHTS RESERVED